Pharmaceutical Biology最新文献

{"title":"Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.","authors":"Guanzhou Ma, Yang Jin","doi":"10.1080/13880209.2024.2415643","DOIUrl":"10.1080/13880209.2024.2415643","url":null,"abstract":"<p><strong>Context: </strong>Bailing capsule, derived from <i>Cordyceps sinensis</i> (Berk.) Sacc. (Clavicipitaceae), has shown potential in the treatment of chronic obstructive pulmonary disease (COPD), a prevalent respiratory disorder.</p><p><strong>Objective: </strong>This study elucidates the efficacy and mechanism of action of the use of Bailing capsules in the treatment of COPD using meta-analysis and network pharmacology.</p><p><strong>Materials and methods: </strong>A meta-analysis of randomized controlled trials (RCTs) was performed. The treatment group received Bailing capsules alongside standard therapy, while the control group received standard therapy or in combination with other traditional Chinese medicines. Efficacy outcomes included lung function, exercise tolerance, acute exacerbation risk, and quality of life. Network pharmacology and molecular docking identified key targets of Bailing capsules.</p><p><strong>Results: </strong>The meta-analysis of 27 RCTs showed significant improvements in the treatment group for forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio, and the 6-min walk test (6MWT). Additionally, there was a marked reduction in acute COPD attacks and an improvement in quality of life. Meanwhile, network pharmacological analysis identified SRC, HIF1A, NFKB1, HDAC2, and PRKACA, as the potential core targets for Bailing capsules in the treatment of COPD.</p><p><strong>Discussion and conclusion: </strong>Bailing capsules have shown promising results in the treatment of stable COPD. Future studies should focus on large-scale, multicenter RCTs to confirm the long-term benefits and safety of Bailing capsules.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials.","authors":"Qun Wang, Hui Xie, Zihong Wang, Runyun Huang, Min Xu, Yongjun Li, Lingling Shan, Hongyan Zhang, Xianghong Liu, Hongxing Zhang, Yunsheng Xu, Shiguang Sun","doi":"10.1080/13880209.2024.2422084","DOIUrl":"10.1080/13880209.2024.2422084","url":null,"abstract":"<p><strong>Context: </strong>Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus. Chinese patent medicines (CPMs) are widely used in clinical practice to treat DPN.</p><p><strong>Objective: </strong>This study aims to summarize the latest evidence on the harms and benefits of CPMs as adjunctive therapy for DPN.</p><p><strong>Materials and methods: </strong>We conducted searches for randomized controlled trials (RCTs) evaluating CPMs in conjunction with mecobalamin (Mec) or alpha-lipoic acid (αLA) across eight databases up to July 2024. The surface under the cumulative ranking area (SUCRA) was utilized to assess the clinical efficacy rate (CER), the peroneal motor nerve conduction velocity (pMNCV), the peroneal sensory nerve conduction velocity (pSNCV), the median motor nerve conduction velocity (mMNCV), and the median sensory nerve conduction velocity (mSNCV).</p><p><strong>Results: </strong>The search yielded 128 eligible studies with 31 CPMs with Mec and 39 eligible studies with 17 CPMs with αLA. SUCRA rankings indicated that, when combined with Mec, <i>Mailuoning</i> liquid (lMLN) was the most effective regimen for CER, <i>Honghua</i> injection (iHH) for pMNCV, <i>Maixuekang</i> capsule (cMXK) for pSNCV, <i>Dengzhanxixin</i> injection (iDZXX) for mMNCV, and <i>Tongxinluo</i> capsule (cTXL) for mSNCV. Combined with αLA, <i>Danhong</i> injection (iDH) showed the highest efficacy for CER, pSNCV, and mSNCV, while <i>Xueshuantong</i> injection (iXShT) was the most effective for pMNCV and mMNCV.</p><p><strong>Conclusion: </strong>This network meta-analysis confirms the efficacy and safety of 37 CPMs combined with Mec or αLA for treating DPN. However, given the potential risk of bias and the very low certainty of the evidence, these recommendations should be adopted with caution.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on the anti-atherosclerosis mechanisms of Tanyu Tongzhi formula based on network pharmacology, Mendelian randomization, and experimental verification.","authors":"Jin Dai, Xinbin Zhou, Xiaoming Xu, Yuangang Qiu, Shenjie Chen, Wei Mao","doi":"10.1080/13880209.2024.2415666","DOIUrl":"10.1080/13880209.2024.2415666","url":null,"abstract":"<p><strong>Context: </strong>Tanyu Tongzhi Formula (TTF) exhibits potential against atherosclerosis; however, its mechanisms remain unclear.</p><p><strong>Objective: </strong>This study explores the pharmacological mechanisms of TTF in treating atherosclerosis.</p><p><strong>Materials and methods: </strong>Network pharmacology, molecular docking, mendelian randomization (MR), and liquid chromatography-mass spectrometry (LC-MS) analyses were utilized to reveal potential targets and compounds of TTF against atherosclerosis. After exploring the appropriate concentration of TTF to treat HCAECs using Cell Counting Kit-8 (CCK-8), the HCAECs were divided into three groups: control, oxidized low-density lipoprotein (ox-LDL, 50 μg/mL), and ox-LDL (50 μg/mL) + TTF (1 mg/mL). After 24-h incubation, the efficacy of TTF was verified by CCK-8, Oil red O staining, and ELISA. The expression of key targets was detected by real-time polymerase chain reaction (qPCR) and western blotting.</p><p><strong>Results: </strong>A total of 137 active compounds and 127 potential TTF targets against atherosclerosis were identified. MR identified ALB, TNF, PPARα, and PPARγ as key targets. Molecular docking indicated that baicalin, naringenin, and curcumin exhibited suitable binding activities to these targets, further confirming by LC-MS analysis. The IC₅₀ of TTF in HCAECs was 18.25 mg/mL. TTF treatment significantly improved atherosclerosis by enhancing cell viability, reducing lipid accumulation, and inhibiting inflammation factors (IL6, IL1B and TNF-α) in ox-LDL-treated HCAECs. Moreover, qPCR or western blotting indicated that TTF could up-regulate PPARα and PPARγ while down-regulate TNF expression.</p><p><strong>Discussion and conclusions: </strong>Our results revealed active compounds, key pathways, and core targets of TTF against atherosclerosis, providing experimental support for its application in treating of atherosclerosis.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review of antimalarial medicinal plants used by Tanzanians.","authors":"David Sylvester Kacholi","doi":"10.1080/13880209.2024.2305453","DOIUrl":"10.1080/13880209.2024.2305453","url":null,"abstract":"<p><strong>Context: </strong>Tanzania has rich medicinal plant (MP) resources, and most rural inhabitants rely on traditional healing practices for their primary healthcare needs. However, available research evidence on antimalarial MPs is highly fragmented in the country.</p><p><strong>Objective: </strong>This systematic review compiles ethnomedicinal research evidence on MPs used by Tanzanians as antimalarials.</p><p><strong>Materials and methods: </strong>A systematic web search was conducted using various electronic databases and grey materials to gather relevant information on antimalarial MPs utilized by Tanzanians. The review was per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The data were collected from 25 articles, and MS Excel software was used to analyse relevant ethnobotanical information using descriptive statistics.</p><p><strong>Results: </strong>A total of 227 MPs belonging to 67 botanical families and 180 genera were identified. Fabaceae (15.9%) is the most frequently utilized family. The ethnobotanical recipes analysis indicated leaves (40%) and trees (44%) are the preferred MPs part and life form, respectively. Decoctions (67%) are the dominant preparation method of remedies. Of the recorded MPs, 25.9% have been scientifically investigated for antimalarial activities with positive results. However, 74.1% of MPs have no scientific records on antimalarial activities, but they could be potential sources of remedies.</p><p><strong>Conclusions: </strong>The study discloses a wealth of antimalarial MPs possessed by Tanzanians and suggests a need for research to authenticate the healing potential of antimalarial compounds from the unstudied MPs. Additionally, it indicates that some of the presented MPs are potential sources for developing safe, effective and affordable antimalarial drugs.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10812860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139547076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing oral bioavailability of andrographolide using solubilizing agents and bioenhancer: comparative pharmacokinetics of <i>Andrographis paniculata</i> formulations in beagle dogs.","authors":"Phanit Songvut, Tussapon Boonyarattanasoonthorn, Nitra Nuengchamnong, Thammaporn Junsai, Teetat Kongratanapasert, Kittitach Supannapan, Phisit Khemawoot","doi":"10.1080/13880209.2024.2311201","DOIUrl":"10.1080/13880209.2024.2311201","url":null,"abstract":"<p><strong>Context: </strong>The therapeutic potential of andrographolide is hindered by its poor oral bioavailability and unpredictable pharmacokinetics, primarily due to its limited water solubility.</p><p><strong>Objective: </strong>This work aimed to enhance the solubility and pharmacokinetics of andrographolide, a bioactive compound in <i>Andrographis paniculata</i> (Burm. f.) Nees (Acanthaceae), using solubilizing agents and a bioenhancer.</p><p><strong>Materials and methods: </strong>Four groups of beagles were compared: (1) <i>A. paniculata</i> powder alone (control), (2) <i>A. paniculata</i> powder with 50% weight/weight (w/w) β-cyclodextrin solubilizer, (3) <i>A. paniculata</i> powder with 1% w/w sodium dodecyl sulfate (SDS) solubilizer, and (4) <i>A. paniculata</i> powder co-administered with 1% w/w SDS solubilizer and 10% piperine bioenhancer. All groups received a consistent oral dose of 3 mg/kg of andrographolide, administered both as a single dose and multiple doses over seven consecutive days.</p><p><strong>Results: </strong>Thirteen chemical compounds were identified in <i>A. paniculata</i> powder, including 7 diterpenoids, 5 flavonoids, and 1 phenolic compound. <i>A. paniculata</i> co-administration with either 50% w/w β-cyclodextrin or 1% w/w SDS, alone or in combination with 10% w/w piperine, significantly increased systemic andrographolide exposure by enhancing bioavailability (131.01% to 196.05%) following single and multiple oral co-administration. Glucuronidation is one possible biotransformation pathway for andrographolide, as evidenced by the excretion of glucuronide conjugates in urine and feces.</p><p><strong>Conclusion: </strong>The combination of solubilizing agents and a bioenhancer improved the oral bioavailability and pharmacokinetics of andrographolide, indicating potential implications for <i>A. paniculata</i> formulations and clinical therapeutic benefits. Further investigation in clinical studies is warranted.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10868414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139730286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Homogeneous <i>Polyporus</i> polysaccharide exerts anti-bladder cancer effects via autophagy induction.","authors":"Siwan Luo, Xiaopeng Huang, Shiqi Li, Yuwen Chen, Xian Zhang, Xing Zeng","doi":"10.1080/13880209.2024.2316195","DOIUrl":"10.1080/13880209.2024.2316195","url":null,"abstract":"<p><strong>Context: </strong>Polyporus polysaccharide (PPS), the leading bioactive ingredient extracted from <i>Polyporus umbellatus</i> (Pers.) Fr. (Polyporaceae), has been demonstrated to exert anti-bladder cancer and immunomodulatory functions in macrophages.</p><p><strong>Objective: </strong>To explore the effects of homogeneous Polyporus polysaccharide (HPP) on the proliferation and autophagy of bladder cancer cells co-cultured with macrophages.</p><p><strong>Materials and methods: </strong>MB49 bladder cancer cells and RAW264.7 macrophages were co-cultured with or without HPP intervention (50, 100, or 200 μg/mL) for 24 h. The cell counting kit-8 (CCK-8) assay and 5-ethynyl-2″-deoxyuridine (EdU) staining evaluated MB49 cell proliferation. Monodansylcadaverine (MDC) staining and transmission electron microscopy (TEM) observed autophagosomes. Western blotting detected the expression levels of autophagy-related proteins and PI3K/Akt/mTOR pathway proteins.</p><p><strong>Results: </strong>HPP inhibited the proliferation of MB49 cells co-cultured with RAW264.7 cells but not MB49 cells alone. HPP altered the expression of autophagy-related proteins and promoted the formation of autophagosomes in MB49 cells in the co-culture system. Autophagy inhibitors 3-methyladenine (3-MA) and chloroquine (CQ) not only antagonized HPP-induced autophagy but also attenuated the inhibitory effects of HPP on MB49 cell proliferation in the co-culture system. HPP or RAW264.7 alone was not sufficient to induce autophagy in MB49 cells. In addition, HPP suppressed the protein expression of the PI3K/Akt/mTOR pathway in MB49 cells in the co-culture system.</p><p><strong>Discussion and conclusions: </strong>HPP induced bladder cancer cell autophagy by regulating macrophages in the co-culture system, resulting in the inhibition of cancer cell proliferation. The PI3K/Akt/mTOR pathway was involved in HPP-induced autophagy in the co-culture system.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10868468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139730287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Traditional Chinese Medicine research in diabetic kidney disease treatment.","authors":"Shiyi Shen, Huiyun Zhong, Xiaoshi Zhou, Guolin Li, Changji Zhang, Yulian Zhu, Yong Yang","doi":"10.1080/13880209.2024.2314705","DOIUrl":"10.1080/13880209.2024.2314705","url":null,"abstract":"<p><strong>Context: </strong>Diabetic kidney disease (DKD) is a prominent complication arising from diabetic microangiopathy, and its prevalence and renal impact have placed it as the primary cause of end-stage renal disease. Traditional Chinese Medicine (TCM) has the distinct advantage of multifaceted and multilevel therapeutic attributes that show efficacy in improving clinical symptoms, reducing proteinuria, protecting renal function, and slowing DKD progression. Over recent decades, extensive research has explored the mechanisms of TCM for preventing and managing DKD, with substantial studies that endorse the therapeutic benefits of TCM compounds and single agents in the medical intervention of DKD.</p><p><strong>Objective: </strong>This review lays the foundation for future evidence-based research efforts and provide a reference point for DKD investigation.</p><p><strong>Methods: </strong>The relevant literature published in Chinese and English up to 30 June 2023, was sourced from PubMed, Cochrane Library, VIP Database for Chinese Technical Periodicals (VIP), Wanfang Data, CNKI, and China Biology Medicine disc (CBM). The process involved examining and summarizing research on TCM laboratory tests and clinical randomized controlled trials for DKD treatment.</p><p><strong>Results and conclusions: </strong>The TCM intervention has shown the potential to inhibit the expression of inflammatory cytokines and various growth factors, lower blood glucose levels, and significantly affect insulin resistance, lipid metabolism, and improved renal function. Furthermore, the efficacy of TCM can be optimized by tailoring personalized treatment regimens based on the unique profiles of individual patients. We anticipate further rigorous and comprehensive clinical and foundational investigations into the mechanisms underlying the role of TCM in treating DKD.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine for breast cancer treatment: a bibliometric and visualization analysis.","authors":"Jun Yuan, Yun Liu, Tiantian Zhang, Cheng Zheng, Xiao Ding, Chuanrong Zhu, Jing Shi, Yi Jing","doi":"10.1080/13880209.2024.2359105","DOIUrl":"10.1080/13880209.2024.2359105","url":null,"abstract":"<p><strong>Context: </strong>The use of traditional Chinese medicine (TCM) for breast cancer patients inhibits tumor cell growth and proliferation, alleviates adverse reactions, and inhibits tumor recurrence and metastasis post-surgery. An assessment of its historical efficacy and an examination of the latest research trends are imperative to thoroughly leverage the potential of TCM for breast cancer treatment.</p><p><strong>Objective: </strong>This study analyzes the published literature on TCM for breast cancer treatment using bibliometric analysis to determine the current state, identify hot spots, and discern trends, providing insight into research in this field.</p><p><strong>Methods: </strong>TCM-based breast cancer treatment publications between 2003 and 2022 were retrieved from the Web of Science, China National Knowledge Infrastructure, Wanfang, and Duxiu databases. Visual analysis was performed using VOSviewer (V1.6.19) and CiteSpace (V6.3.R1) software. Examined metrics included the annual publication count, literature and journal, national and institutional contributions, author co-occurrence, keyword co-occurrence, keywords timeline, and keywords with citation bursts in this research field.</p><p><strong>Results and conclusion: </strong>A total of 1080 English publications and 2617 Chinese publications were included in the analysis. China was the leading contributor of publications. High-frequency keywords such as 'apoptosis', 'expression', '<i>in vivo</i>', 'chemotherapy', 'triple-negative breast cancer', and 'lymphedema' were identified from English and Chinese publications; 'epithelial mesenchymal transition' and 'network pharmacology' emerged as hotspots. The development of modern science, technology, and in-depth research can result in broader prospects for the research and application of TCM in breast cancer treatment, resulting in more effective solutions for the treatment of breast cancer and other malignant tumors.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proanthocyanidin offers protection against diabetic nephropathy: elucidation of its mechanism of action using animal models.","authors":"Dengpiao Xie, Huan Wang, Qing Ji, Jianting Wang","doi":"10.1080/13880209.2024.2409772","DOIUrl":"10.1080/13880209.2024.2409772","url":null,"abstract":"<p><strong>Context: </strong>Diabetic nephropathy (DN) is a major complication of diabetes mellitus and is the leading cause of kidney disease in patients undergoing renal replacement therapy. DN is associated with an increased risk of death in patients with diabetes. Conventional therapy for DN includes intensive control of blood glucose level and blood pressure and renin-angiotensin system blockade. However, this approach has limited treatment effects on DN. Therefore, identifying novel drugs to delay the progression of DN is urgently needed. Proanthocyanidin (PA) has been shown to exert potentially beneficial effects on DN. However, the protective mechanism and efficacy are yet to be elucidated.</p><p><strong>Objective: </strong>This study evaluates the efficacy and potential mechanisms of PA in animal models of DN.</p><p><strong>Methods: </strong>Preclinical studies were searched from Chinese National Knowledge Infrastructure, PubMed, Web of Science, Embase, and Google Scholar databases, with the search deadline of August 2023. Keywords ('diabetic nephropathies', 'nephropathies, diabetic', 'diabetic kidney diseases', 'proanthocyanidin', 'anthocyanidin polymers', 'procyanidins', 'animal*', 'rat', and 'mice') were used to search the databases. RevMan 5.3 was used for statistical analysis.</p><p><strong>Results: </strong>A total of 22 studies involving 538 animals were included in this analysis. The pooled results indicated that PA therapy significantly improved kidney function and reduced proteinuria and blood glucose levels. The protective mechanism of PA was associated with anti-inflammatory, antioxidant, antifibrotic, and antiapoptotic effects; inhibition of endoplasmic reticulum stress; and alleviation of mitochondrial dysfunction and dyslipidemia.</p><p><strong>Conclusion: </strong>These findings suggest that PA alleviates DN by mediating multiple targets and pathways.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.","authors":"Yadong Ni, Xianglong Wu, Wenhui Yao, Yuna Zhang, Jie Chen, Xuansheng Ding","doi":"10.1080/13880209.2024.2374794","DOIUrl":"10.1080/13880209.2024.2374794","url":null,"abstract":"<p><strong>Context: </strong>The global prevalence of type 2 diabetes mellitus (T2DM) has increased significantly in recent decades. Despite numerous studies and systematic reviews, there is a gap in comprehensive and up-to-date evaluations in this rapidly evolving field.</p><p><strong>Objective: </strong>This review provides a comprehensive and current overview of the efficacy of Traditional Chinese Medicine (TCM) in treating T2DM.</p><p><strong>Methods: </strong>A systematic review was conducted using PubMed, Web of Science, Wanfang Data, CNKI, and Medline databases, with a search timeframe extending up to November 2023. The search strategy involved a combination of subject terms and free words in English, including 'Diabetes,' 'Traditional Chinese Medicine,' 'TCM,' 'Hypoglycemic Effect,' 'Clinical Trial,' and 'Randomized Controlled Trial.' The studies were rigorously screened by two investigators, with a third investigator reviewing and approving the final selection based on inclusion and exclusion criteria.</p><p><strong>Results: </strong>A total of 108 relevant papers were systematically reviewed. The findings suggest that TCMs not only demonstrate clinical efficacy comparable to existing Western medications in managing hypoglycemia but also offer fewer adverse effects and a multitarget therapeutic approach. Five main biological mechanisms through which TCM treats diabetes were identified: improving glucose transport and utilization, improving glycogen metabolism, promoting GLP-1 release, protecting pancreatic islets from damage, and improving intestinal flora.</p><p><strong>Conclusions: </strong>TCM has demonstrated significant protective effects against diabetes and presents a viable option for the prevention and treatment of T2DM. These findings support the further exploration and integration of TCM into broader diabetes management strategies.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}